

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 1/27/1948
Sex: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 01/01/2017 12:34

Lurasidone Quantitative, Serum or Plasma

ARUP test code 2013018

Lurasidone Quantitative, Serum/Plasma

None Det ng/mL

Serum
Reporting Limit: 2.5 ng/mL

Synonym(s): Latuda(R)
Following single dose administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 54 and 64 ng/mL, respectively. Following steady-state administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 48 and 79 ng/mL, respectively.
Peak serum concentrations and absorption occur in approximately 1 to 3 hours. Steady-state concentrations are reached within 7 days of initiation of therapy. The elimination half-life is approximately 18 hours.
The white blood cell (WBC) count should be monitored periodically, because agranulocytosis, leukopenia, and neutropenia have been reported during clinical trials.
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.
Testing performed at NMS Labs, Inc.
200 Welsh Road
Horsham, PA 19044-2208
CLIA 39D0197898

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Lurasidone Quantitative, Serum/Plasma	22-102-145842	4/12/2022 12:00:00 AM	4/15/2022 11:55:43 AM	4/20/2022 2:31:00 PM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: